<html><head><link rel="stylesheet" href="https://unpkg.com/mvp.css"></head><title>Meeting of Drug Regulators of India and China</title><body><h1>Meeting of Drug Regulators of India and China</h1><p style="text-align:justify">A one-day workshop on regulatory systems in the pharma sector,was jointly organized by National Medical Products Administration (NMPA, erstwhile CFDA) and Central Drugs Standard Control Organisation (CDSCO) for the benefit of Indian pharmaceutical companies on 21st June, 2019 in Shanghai, China. </p>
<p style="text-align:justify">The intensive day-long workshop included detailed deliberations in areas such as regulatory overview of NMPA, registration of imported drugs in China, Indian regulatory system, drug procurement system in China, NMPA overseas inspections and compliance guide, API (Active Pharmaceutical Ingredient) registration process in China and compliance guide. Both sides also decided to work towards greater coordination and cooperation between the two regulators in the future.</p>
<p style="text-align:justify">India has requested China to open its pharmaceuticals market, especially for affordable and high quality generic drugs from Indian pharma companies. India has also asked China to clear the various regulatory hurdles faced by the Indian pharma companies on priority, including long delays in product approval timelines, lack of clarity in the current registration guidelines, waiver for bio-equivalence (BE) studies and local clinical trials, drug procurement by local governments in China, suomotu approvals for those Indian pharma companies which have approvals from stringent regulatory authorities like USFDA, EDQM, Japan and ‘risk based’ batch testing with self-certification. The steps taken to enhance and encourage the exports of pharma products, including high standard generics, from India to China are given below:</p>
<p style="text-align:justify">Steps taken for enhancing and encouraging exports of pharma products, including high standard generics, from India to China</p>
<p style="text-align:justify">This information was given by the Minister of Commerce and Industry, Piyush Goyal, in a written reply in the Rajya Sabha today.</p>
<p style="text-align:justify">***</p>
<p style="text-align:justify">
</body></html>